Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush

Inozyme Pharma, Inc. (NASDAQ:INZY) – Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Inozyme Pharma in a research note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.43) per share for the quarter. Wedbush currently has a “Outperform” rating and a $7.00 target price on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.80) EPS.

Several other equities analysts also recently commented on INZY. Needham & Company LLC lowered their target price on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday. Wells Fargo & Company lowered their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a research note on Tuesday. Raymond James dropped their price objective on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Piper Sandler dropped their price objective on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $14.56.

Inozyme Pharma Trading Up 1.9 %

NASDAQ INZY opened at $1.08 on Thursday. Inozyme Pharma has a 1-year low of $0.98 and a 1-year high of $7.80. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $69.38 million, a PE ratio of -0.69 and a beta of 1.32. The firm’s fifty day simple moving average is $1.52 and its 200-day simple moving average is $3.28.

Institutional Investors Weigh In On Inozyme Pharma

A number of institutional investors have recently added to or reduced their stakes in INZY. OneDigital Investment Advisors LLC grew its position in Inozyme Pharma by 51.5% during the third quarter. OneDigital Investment Advisors LLC now owns 20,000 shares of the company’s stock worth $105,000 after buying an additional 6,800 shares in the last quarter. Eventide Asset Management LLC grew its position in Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock worth $21,623,000 after buying an additional 198,216 shares in the last quarter. Readystate Asset Management LP acquired a new stake in Inozyme Pharma during the third quarter worth about $100,000. State Street Corp grew its position in Inozyme Pharma by 5.0% during the third quarter. State Street Corp now owns 1,050,420 shares of the company’s stock worth $5,494,000 after buying an additional 50,386 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in Inozyme Pharma by 11.9% during the third quarter. Wellington Management Group LLP now owns 260,719 shares of the company’s stock worth $1,364,000 after buying an additional 27,739 shares in the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.